The July 2026 FDA Peptide Vote, Explained

The Pharmacy Compounding Advisory Committee (PCAC) is a panel of outside experts that advises the FDA. Its job at this meeting was to recommend whether each peptide should go on the 503A bulks list. That's the federal list of ingredients that compounding pharmacies may use to make custom medications, even though the ingredients aren't part of an FDA-approved drug.

The seven peptides were BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), Semax, and Epitalon. All seven had been blocked from compounding since 2023, when the FDA flagged them for safety risks.

Before the meeting, FDA reviewers recommended that none of the seven be added. Their concerns included limited human clinical evidence, uncertain safety and effectiveness, open questions about the products' composition and stability, and thin support for the proposed medical uses. For BPC-157, staff also noted that approved treatments already exist for ulcerative colitis, the condition it was nominated for.

Peptide	Committee vote	Date
BPC-157	Recommended, 8–6 (1 abstention)	July 23
KPV	Recommended, 8–6 (1 abstention)	July 23
TB-500	Recommended, 8–6 (1 abstention)	July 23
MOTS-c	Recommended, 7–5 (2 abstentions)	July 23
Semax	Recommended	July 24
Epitalon	Recommended	July 24
Emideltide (DSIP)	Not recommended	July 24

Several members acknowledged the evidence was thin. Those voting yes argued that people are already using these peptides, and that regulated pharmacies would be safer than the gray market. Critics pointed to the lack of new safety data since 2023 and to some panel members' ties to the peptide industry.

Very little, legally. Advisory votes don't bind the FDA. The vote didn't approve any peptide as a drug, and it didn't add anything to the bulks list.

The FDA has a few steps before any of these peptides can legally be compounded:

1. Review the public record. The FDA considers comments and data submitted to the meeting's docket.
2. Publish a proposed rule. This says which peptides the FDA plans to add, if any. The FDA can follow the committee, overrule it, or split the difference.
3. Take public comments, then publish a final rule. Only then would a peptide be on the bulks list.

That process typically takes many months; compounding observers don't expect it to finish before mid-to-late 2027.

There's also a faster possible path. On October 14, 2026, the FDA sent an interim access policy for compounding certain peptides to the White House budget office. If it clears review, it could allow temporary compounding of some peptides while the formal process continues.

The committee is scheduled to meet again in February 2027 to review five more peptides: cathelicidin, GHK-Cu, dihexa acetate, Melanotan II, and PEG-MGF.

See where each peptide stands today on our FDA status tracker.